Is BioCardia, Inc. (BCDA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 7.6% / 30% | 18.9% / 30% | 0.0% / 30% | 94.83% / 5% | ✗ NOT HALAL |
| DJIM | 7.6% / 33% | 18.9% / 33% | 0.0% / 33% | 94.83% / 5% | ✗ NOT HALAL |
| MSCI | 25.5% / 33% | 63.7% / 33% | 0.0% / 33% | 94.83% / 5% | ✗ NOT HALAL |
| S&P | 7.6% / 33% | 18.9% / 33% | 0.0% / 33% | 94.83% / 5% | ✗ NOT HALAL |
| FTSE | 25.5% / 33% | 63.7% / 33% | 0.0% / 50% | 94.83% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -950.1% | |
| Return on Assets (ROA) | -145.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$8M |
| Free Cash Flow | -$8M |
| Total Debt | $951,000 |
| Debt-to-Equity | 59.0 |
| Current Ratio | 1.1 |
| Total Assets | $4M |
Price & Trading
| Last Close | $1.18 |
| 50-Day MA | $1.24 |
| 200-Day MA | $1.57 |
| Avg Volume | 80K |
| Beta | 0.6 |
|
52-Week Range
$1.00
| |
About BioCardia, Inc. (BCDA)
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is BioCardia, Inc. (BCDA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), BioCardia, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is BioCardia, Inc.'s debt ratio?
BioCardia, Inc.'s debt ratio is 7.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 25.5%.
What are BioCardia, Inc.'s key financial metrics?
BioCardia, Inc. has a market capitalization of $12M, and revenue of $58,000. Return on equity stands at -950.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.